Microphysiological Systems Market Expected to Reach $370 Million by 2031, Driven by Demand for Next-Generation Drug Testing Models

Pune, India – October 15, 2025: The global market for Microphysiological Systems (MPS) – advanced “organ-on-a-chip” platforms that replicate human organ functions in vitro – is projected to experience robust growth over the next decade. According to a recent industry report, the Global Microphysiological Systems Market, valued at approximately USD $126.4 million in 2024, is forecast to reach USD $370.3 million by 2031, achieving a CAGR of 16.23% during 2025-2031. This strong double-digit growth reflects rising demand for more human-relevant, efficient, and ethical tools in biomedical research and drug development.

Microphysiological Systems have emerged as revolutionary alternatives to traditional cell culture and animal testing, allowing researchers and pharmaceutical companies to study biological processes, drug efficacy, and toxicity with unprecedented precision.These micro-engineered devices (often the size of a USB stick or smaller) are lined with living cells and tissues, mimicking the structural and functional characteristics of human organs. By recreating human physiology on a micro-scale, MPS offer a predictive model of human responses that can improve the success rate of drug discovery and safety testing. Conventional animal models often fail to accurately predict human drug responses, leading to late-stage clinical failures.MPS address this challenge by providing more accurate, human-relevant models, which is a key factor driving their adoption across the life sciences industry.

Get PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) https://www.qyresearch.in/request-sample/service-software-global-microphysiological-system-market-insights-industry-share-sales-projections-and-demand-outlook-2025-2031

Market Overview and Growth Outlook

The Microphysiological Systems market encompasses a range of organ-on-chip and tissue-engineered platforms designed for drug discovery, toxicity screening, disease modeling, and personalized medicine applications. With both quantitative and qualitative analysis, recent market research provides a comprehensive outlook through 2031 to help industry stakeholders develop growth strategies and make informed decisions. Key findings indicate that the market will nearly triple in size by 2031, underpinned by technological advancements and expanding use cases in pharmaceuticals and academia. The period from 2020 to 2024 saw steady adoption of MPS, and this is expected to accelerate significantly through 2025-2031 as these systems transition from early R&D into more routine use in drug pipelines.

Several market drivers are propelling this growth trajectory:

Need for Predictive Drug Testing Models: Pharmaceutical and biotechnology companies are seeking more predictive and cost-effective models for preclinical testing. MPS enable high-throughput screening and toxicity assessments on human-derived cells, reducing dependency on animal models and improving the odds of identifying viable drug candidates earlier.This can mitigate the risk of late-stage failures and reduce R&D costs by providing better data on human responses before clinical trials.

Ethical and Regulatory Pressure to Reduce Animal Testing: There is a global shift toward ethical research practices and regulatory encouragement for alternatives to animal testing.Stricter animal welfare laws, especially in Europe, and consumer advocacy for cruelty-free product development (notably in cosmetics and chemical safety testing) are compelling researchers to adopt non-animal models. MPS offer a credible solution, and as regulators increasingly recognize organ-on-chip data for toxicity and efficacy studies, industry uptake is growing.This trend is bolstered by government and institutional funding for non-animal testing methodologies.

Advancements in Tissue Engineering and Microfluidics: Continuous technological innovation – including improvements in biomaterials, microfluidic design, and 3D cell culture techniques – has enhanced the performance and reliability of microphysiological systems.Modern MPS devices can maintain living cells in organ-mimicking microenvironments for extended periods, allowing more complex and physiologically accurate experiments. These advancements are broadening the scope of MPS applications (e.g. multi-organ “body-on-a-chip” systems) and lowering barriers to adoption by providing more user-friendly, scalable platforms.

Rise of Personalized Medicine and Disease Modeling: The growing emphasis on personalized medicine and the need to model specific diseases in vitro is another major driver. MPS can be created using patient-derived cells (including stem cells), enabling researchers to simulate individual patient organ responses or genetic diseases on a chip.This capability supports the development of targeted therapies and rare disease research. Additionally, MPS disease models (chips replicating disease conditions such as cancer tumors, fibrotic tissue, or neurological disorders) allow scientists to study pathology and test new treatments in a controlled setting that closely mirrors human disease biology.The demand for such tailored, disease-specific models is accelerating as pharmaceutical pipelines increasingly include precision medicines.

Key Market Trends

In tandem with these drivers, several important market trends are shaping the microphysiological systems industry:

Multi-Organ Integrated Systems: Researchers and MPS companies are moving beyond single-organ models toward linked organ systems on chips. Connecting multiple organ modules (for example, a liver-chip with a heart-chip and kidney-chip) via microfluidic channels can simulate whole-body pharmacokinetics and organ-organ interactions. This trend addresses the complexity of human biology, providing more comprehensive data on how a drug or chemical might affect different organ systems together. While still emerging, multi-organ “body-on-a-chip” platforms are expected to gain traction as an advanced tool for systems biology and drug metabolism studies.

Broadening Application Areas: Initially focused on drug toxicity and efficacy testing for pharmaceuticals, MPS adoption is expanding into new sectors. The cosmetics industry, facing bans on animal testing in regions like Europe, is exploring organ-on-chip models for safety testing of ingredients (e.g., skin or eye irritation chips).Environmental agencies and chemical manufacturers are investigating MPS for toxicity screening of chemicals (e.g., liver-on-chip for assessing industrial chemical exposure). Moreover, academic research institutes are using MPS to study fundamental biology and disease mechanisms, often in collaboration with medical centers, which underscores their scientific value beyond commercial drug development.

Collaborations and Consortia: A notable trend is the formation of strategic partnerships among stakeholders. Leading MPS companies are collaborating with big pharmaceutical firms, regulatory agencies, and research institutions to validate and standardize MPS technology. For instance, Emulate, Inc. – one of the pioneers in this field – has established partnerships with major drug developers (such as Roche, Takeda, Merck, Johnson & Johnson) and even a cooperative research agreement with the U.S. FDA to accelerate organ-on-chip validation.Such collaborations help build industry confidence in MPS data, integrate these systems into pharmaceutical R&D workflows, and often come with funding that supports further innovation. Consortia and public-private partnerships (including initiatives by regulatory bodies or industry coalitions) are working on setting standards for MPS and sharing best practices, which will facilitate broader adoption across labs.

Commercialization and Product Development: As the market matures, companies are focusing on improving the usability and scalability of MPS products. Trends include developing user-friendly instrumentation (pumps, sensors, and software) to accompany the chips, enabling automated culture monitoring and data analysis. There is also an emphasis on standardized consumables and kits that allow labs to run organ-on-chip experiments without needing highly specialized setups. Some providers are expanding their product portfolios to cover a wider range of organ models (e.g., lung, liver, gut, brain, kidney chips) and disease states, often guided by industry demand for models of particular toxicity or disease areas. This broadening of product offerings is expected to continue, making MPS more accessible and versatile for end users.

Request Pre-Order Enquiry or Customized Research On This Report:  https://www.qyresearch.in/pre-order-inquiry/service-software-global-microphysiological-system-market-insights-industry-share-sales-projections-and-demand-outlook-2025-2031

Market Scope and Segmentation

The scope of the microphysiological systems market spans various model types, end-use industries, and geographies. In the report, the market is segmented as follows:

By Type:

• Human Organ & Tissue Models – e.g., chips mimicking human organs such as liver, heart, lung, kidney, brain, or composite tissues. These models are widely used as alternatives to animal organs for testing drug metabolism, toxicity, and efficacy in human biology contexts.
• Disease Models – chips designed to represent specific disease conditions (for instance, a liver fibrosis-on-chip, tumor-on-chip, or asthma lung model). These enable the study of disease progression and therapeutic screening in a controlled environment that reflects the diseased state.
• Non-Human Species Models – models that use cells/tissues from non-human species, typically to study veterinary applications or to serve as proxies for environmental toxicology (for example, fish gill chips for water toxicity, or chips with animal cells to predict cross-species responses). While a smaller segment, these models support research where human analogs are not the only focus.

By End User:

• Pharmaceutical & Biotechnology Companies – the primary end users, utilizing MPS in drug development pipelines for candidate screening, lead optimization, and safety testing. This segment drives a large portion of demand as companies seek to reduce costly clinical failures by improving preclinical prediction.Many big pharma companies are either partnering with MPS providers or building in-house organ-on-chip programs to integrate this technology into their R&D.
• Academic & Research Institutes – universities, government labs, and non-profit research organizations that use MPS to advance basic science and to develop new models. Academics often spearhead novel uses of MPS (such as modeling complex diseases or exploring organ physiology) and collaborate with industry to translate their findings. Their role is critical in innovation and training the next generation of researchers in these technologies.
• Others – this includes sectors like cosmetics, personal care, and chemical industry labs, as well as Contract Research Organizations (CROs) offering MPS-based testing services. Cosmetics companies, for example, are increasingly using human skin or ocular tissue chips for product safety assessment due to bans on animal testing. Regulatory agencies and toxicology testing labs also fall in this category, as they explore MPS for risk assessment of drugs and chemicals.

Geographically, the report covers market size and forecasts for North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. The analysis considers country-level data in key markets such as the United States, Canada, China, Japan, Germany, the U.K., and others, highlighting regional trends and growth opportunities.

Regional Insights

North America currently leads the global microphysiological systems market, accounting for the largest revenue share. In 2024, North America’s MPS market was approximately $55.2 million (about 43% of the global market) and is projected to reach $154.4 million by 2031 (CAGR of 15.3% from 2025-2031). Growth in North America is fueled by the region’s robust pharmaceutical industry and extensive R&D funding, especially in the United States.A supportive regulatory environment – including openness to evaluating non-animal testing data – and the presence of leading MPS companies and top research universities have further anchored North America’s leadership in this sector.The U.S. government and agencies like the NIH have also invested in organ-on-chip research programs over the past decade, contributing to technology development and early adoption.

Europe is the second-largest market for MPS. Valued at around $51.8 million in 2024, Europe’s MPS market is forecast to grow to $147.7 million by 2031 (CAGR of 15.8% during 2025-2031). The European growth is driven by stringent ethical regulations and a proactive stance on reducing animal testing.The European Union’s ban on animal testing for cosmetics and the push for the “3Rs” (Replacement, Reduction, Refinement of animal use in research) have accelerated interest in human-relevant test methods. Additionally, Europe has strong academic and biotech collaboration networks, with countries like Germany, the UK, France, and the Netherlands housing active organ-on-chip research hubs and startups. These collaborative ecosystems help in technology exchange and validation studies, which bolster market acceptance. European initiatives (such as Horizon-funded consortia in organ-on-chip) also provide funding and platforms for MPS development, thereby fostering market growth.

Asia-Pacific (APAC) represents the fastest-growing region for microphysiological systems. Although smaller in current market size (approx. $15.1 million in 2024), the APAC MPS market is projected to reach $53.7 million by 2031, registering a high CAGR of 19.6% through the forecast period. Several factors contribute to this rapid growth. There is surging investment in biotechnology and pharmaceutical R&D across Asia, particularly in China, Japan, and South Korea, which are developing as innovation hubs for biomedical technology.Governments in these countries have launched programs to advance tissue engineering and precision medicine, providing funding that supports MPS research. Local startups and research institutions in Asia are beginning to produce home-grown MPS solutions, often through technology transfer or partnerships with Western counterparts, thereby increasing regional availability. Additionally, the large patient populations and increasing clinical trial activity in Asia create a demand for better preclinical testing tools, a role MPS can fulfill. India and Southeast Asian countries are also gradually adopting organ-on-chip platforms, aided by growing awareness and the presence of multinational pharma R&D centers in these regions. APAC’s market, while starting from a lower base, is expected to steadily expand as both the public and private sectors recognize the value of microphysiological systems in research and safety testing.

Other regions, including Latin America and the Middle East & Africa, currently form a smaller portion of the global MPS market but are witnessing emerging interest. In Latin America, countries like Brazil are investing in biotech research which could drive future MPS adoption. The Middle East (e.g., Gulf states) has shown interest through academic research funding in biomedical engineering. While concrete market figures for these regions remain modest, they are anticipated to grow as global technology diffusion continues.

Competitive Landscape

The competitive landscape of the microphysiological systems market is dynamic, characterized by a mix of specialized biotechnology firms, academic spin-offs, and collaborative research organizations. According to the industry report, the top five companies account for roughly 48.8% of the global market revenue in 2024, indicating a moderately consolidated market where a handful of leaders have significant influence. Key players identified in the global MPS market include Emulate, Mimetas, TissUse, InSphero, and CN Bio, among others. These companies have been at the forefront of organ-on-chip innovation, offering diverse platform technologies and forming partnerships with end users. For instance, Emulate (US) and Mimetas (Netherlands) are known for their robust portfolios of organ-specific chips and user-friendly systems, while Germany’s TissUse has developed multi-organ chip platforms. Swiss-based InSphero integrates organoids with microfluidics, and UK’s CN Bio Innovations provides multi-organ liver-focused devices – showcasing the range of technical approaches in this sector.

Competition in this market largely revolves around innovation, performance, and strategic alliances rather than sheer volume manufacturing. Companies are striving to improve the biological fidelity of their models (e.g., ensuring that chips accurately mimic human organ functions and responses) and the throughput (e.g., the ability to run many experiments in parallel for screening purposes). Product differentiation is achieved through offering unique organ models, proprietary biomaterials, or integrated software that simplifies data analysis. For example, some vendors emphasize specific strengths – one might offer the best lung-on-chip model, while another specializes in inflammatory disease chips – allowing multiple players to carve out niches.

In conclusion, the microphysiological systems market is poised for strong growth and transformative impact on how drugs and chemicals are tested for safety and efficacy. By 2031, with an estimated market size of $370 million and global adoption on the rise, MPS technology is moving from the fringes of experimental research to the center stage of preclinical development. Industry stakeholders – from investors to pharmaceutical executives and research scientists – are keenly watching this space as it promises not only financial growth but also the potential to fundamentally improve human health outcomes. The convergence of market drivers such as demand for better predictive models, ethical imperatives, and technological innovations positions microphysiological systems as a critical component of the future biomedical toolkit. Companies that adapt to and invest in this trend are expected to gain a competitive edge in drug development efficiency and a reputation for innovation in the years to come.

Overall, the next decade will likely see microphysiological systems evolving from a cutting-edge concept to a standard industry practice, much like how cell culture became ubiquitous in the past. With collaborative efforts, sustained R&D, and a clear value proposition, the MPS market’s growth story appears solid, offering significant opportunities for stakeholders across the scientific and commercial spectrum.

For Further insights and Detailed Reports, Visit: https://www.qyresearch.in/report-details/7834615/Global-Microphysiological-System-Market-Insights

About US:

QYResearch is a leading global market research and consulting company established in 2007. With over 17 years’ experience and professional research team in various cities over the world QY Research focuses on management consulting, database and seminar services, IPO consulting, industry chain research and customized research to help our clients in providing non-linear revenue model and make them successful. We are globally recognized for our expansive portfolio of services, good corporate citizenship, and our strong commitment to sustainability.

Contact US

QY Research, INC.

India Office -

315Work Avenue, Raheja Woods, Kalyani Nagar, 

Pune, Maharashtra 411006, India

Web – https://www.qyresearch.in

Email- ankit@qyresearch.com 

Other Related Report From QY Research:

1. Lab-on-a-chip (LOC) — Global Market Insights, Industry Share, Sales Projections and Demand Outlook, 2025–2031. (qyresearch.in)
2. Microfluidic Chips — Global Market Insights, Industry Share, Sales Projections and Demand Outlook, 2025–2031. (qyresearch.in)
3. Polymer-based Microfluidic Chips — Global Market Insights, Industry Share, Sales Projections and Demand Outlook, 2025–2031. (qyresearch.in)
4. Microfluidic Droplet Chip — Global Market Insights, Industry Share, Sales Projections and Demand Outlook, 2025–2031. (qyresearch.in)
5. Microfluidic Glass — Global Market Share & Ranking, Overall Sales and Demand Forecast, 2025–2031. (qyresearch.in)
6. Microfluidic Element — Global Market Insights, Industry Share, Sales Projections and Demand Outlook, 2025–2031. (qyresearch.in)
7. Brain-on-chip — Global Market Insights, Industry Share, Sales Projections and Demand Outlook, 2025–2031. (qyresearch.in)
8. 3D Cell Culture Consumables — Global Market Insights, Industry Share, Sales Projections and Demand Outlook, 2025–2031. (qyresearch.in)
9. 3D Cell Culture Hydrogel — Global Market Insights, Industry Share, Sales Projections and Demand Outlook, 2025–2031. (qyresearch.in)
10. Organoid Culture and Differentiation — Global Market Insights, Industry Share, Sales Projections and Demand Outlook, 2025–2031. (qyresearch.in)